Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414047 · ClinicalTrials.gov registry record · Phase 2
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 20
- Study locations
NCT03414047 is a Phase 2 study of Ovarian Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 172 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03414047, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
Conditions Studied
Interventions
- DRUG Prexasertib
Study Locations (20)
Tennessee
- University of Tennessee Medical Center - Knoxville
- Sarah Cannon Research Institute SCRI - Nashville
- Tennessee Oncology PLLC - Nashville
New South Wales
- Concord Repatriation General Hospital - Concord
- Prince of Wales Hospital - Randwick
- Westmead Hospital - Wentworthville
Queensland
- Royal Brisbane and Womens Hospital - Herston
- Mater Adult Hospital Brisbane - South Brisbane
Arizona
- Arizona Oncology Associates, P.C. - Tucson
California
- Kaiser Permanente Medical Center - Vallejo
Florida
- University of Southern Florida School of Medicine - Gainesville
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Research Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2020-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03414047
The ClinicalTrials.gov registry entry for NCT03414047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prexasertib is the first listed.
NCT03414047 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Tennessee, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT03414047 about?
NCT03414047 is a clinical study titled "A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer". The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
What is the current status of trial NCT03414047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2018-04-10. Estimated completion is 2020-10-03.
What conditions does trial NCT03414047 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03414047?
The interventions under investigation include: Prexasertib (DRUG).
Who is sponsoring clinical trial NCT03414047?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03414047 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.